These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 37061987)
1. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987 [TBL] [Abstract][Full Text] [Related]
2. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development. Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168 [TBL] [Abstract][Full Text] [Related]
3. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Vranic S; Basu GD; Hall DW; Gatalica Z Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315 [TBL] [Abstract][Full Text] [Related]
4. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671 [TBL] [Abstract][Full Text] [Related]
5. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371 [TBL] [Abstract][Full Text] [Related]
6. [Current Status and Challenges in Tumor Agnostic Treatment]. Komine K Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595 [TBL] [Abstract][Full Text] [Related]
7. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine. Seligson ND; Knepper TC; Ragg S; Walko CM Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906 [TBL] [Abstract][Full Text] [Related]
8. Precision medicine becomes reality-tumor type-agnostic therapy. Yan L; Zhang W Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494 [TBL] [Abstract][Full Text] [Related]
9. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Adashek JJ; Subbiah V; Kurzrock R Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795 [TBL] [Abstract][Full Text] [Related]
10. If it's a target, it's a pan-cancer target: Tissue is not the issue. Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181 [TBL] [Abstract][Full Text] [Related]
11. Impact of tissue-agnostic approvals on management of primary brain tumors. Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379 [TBL] [Abstract][Full Text] [Related]
12. The evolving landscape of tissue-agnostic therapies in precision oncology. Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R CA Cancer J Clin; 2024; 74(5):433-452. PubMed ID: 38814103 [TBL] [Abstract][Full Text] [Related]
13. Tissue-Agnostic Cancer Therapy Approvals. Gouda MA; Subbiah V Surg Oncol Clin N Am; 2024 Apr; 33(2):243-264. PubMed ID: 38401908 [TBL] [Abstract][Full Text] [Related]
14. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210 [TBL] [Abstract][Full Text] [Related]
15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
16. Tissue-Agnostic Drug Development: A New Path to Drug Approval. Thein KZ; Lemery SJ; Kummar S Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971 [TBL] [Abstract][Full Text] [Related]
17. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer]. Peták I Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351 [TBL] [Abstract][Full Text] [Related]
18. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Pestana RC; Serrano C Front Oncol; 2022; 12():1079909. PubMed ID: 36741731 [TBL] [Abstract][Full Text] [Related]
19. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552 [TBL] [Abstract][Full Text] [Related]
20. Impact of tissue-agnostic approvals for patients with sarcoma. Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]